Longeveron

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 25

Market Cap: $32.7M

Website

Clinical Trials

Lomecel-B Effects on Alzheimer's Disease

Phase 2

Completed

Conditions: Mild Alzheimer's Disease

Interventions: Other: Placebo
Drug: Allogeneic MSC

First Posted Date: 2022-02-10

Last Posted Date: 2024-02-20

Lead Sponsor: Longeveron Inc.

Target Recruit Count: 50

Registration Number: NCT05233774

Locations: 🇺🇸
Imic Inc., Palmetto Bay, Florida, United States
🇺🇸
Visionary Investigators Network, Aventura, Florida, United States
🇺🇸
Science Connections - Research Partner Group Multispecialty Group, Doral, Florida, United States

and more 9 locations

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Phase 2

Recruiting

Conditions: Hypoplastic Left Heart Syndrome

Interventions: Biological: Lomecel-B medicinal signaling cells

First Posted Date: 2021-06-14

Last Posted Date: 2024-10-16

Lead Sponsor: Longeveron Inc.

Target Recruit Count: 38

Registration Number: NCT04925024

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 9 locations

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

Phase 1

Active, not recruiting

Conditions: ARDS, Human
Covid19

Interventions: Other: Placebo
Biological: Longeveron Mesenchymal Stem Cells (LMSCs)

First Posted Date: 2020-11-16

Last Posted Date: 2024-02-20

Lead Sponsor: Longeveron Inc.

Target Recruit Count: 70

Registration Number: NCT04629105

Locations: 🇺🇸
Miami VA Healthcare System, Miami, Florida, United States
🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)

Phase 1

Active, not recruiting

Conditions: HLHS

Interventions: Biological: Longeveron Mesenchymal Stem Cells

First Posted Date: 2018-05-15

Last Posted Date: 2023-10-04

Lead Sponsor: Longeveron Inc.

Target Recruit Count: 10

Registration Number: NCT03525418

Locations: 🇺🇸
Johns Hopkins University Hospital, Baltimore, Maryland, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

and more 2 locations

Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty

Phase 2

Completed

Conditions: Aging Frailty

Interventions: Biological: Longeveron Mesenchymal Stem Cells (LMSCs)
Other: Placebo

First Posted Date: 2017-05-30

Last Posted Date: 2022-03-07

Lead Sponsor: Longeveron Inc.

Target Recruit Count: 150

Registration Number: NCT03169231

Locations: 🇺🇸
Soffer Health Institute, Aventura, Florida, United States
🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Clinical Physiology Associates, Fort Myers, Florida, United States

and more 4 locations

Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty

Phase 1

Completed

Conditions: Aging Frailty

Interventions: Biological: Longeveron Mesenchymal Stem Cells (LMSCs)
Biological: Fluzone High Dose Vaccine

First Posted Date: 2016-12-06

Last Posted Date: 2022-11-04

Lead Sponsor: Longeveron Inc.

Target Recruit Count: 62

Registration Number: NCT02982915

Locations: 🇺🇸
Optimal Research LLC, Rockville, Maryland, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Clinical Physiology Associates, Fort Myers, Florida, United States

and more 3 locations

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Biological: Longeveron Mesenchymal Stem Cells
Biological: Placebo

First Posted Date: 2015-11-09

Last Posted Date: 2021-12-14

Lead Sponsor: Longeveron Inc.

Target Recruit Count: 33

Registration Number: NCT02600130

Locations: 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
Miami Jewish Health, Miami, Florida, United States
🇺🇸
Brain Matters Research, Delray Beach, Florida, United States

Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial

Phase 2

Withdrawn

Conditions: Metabolic Disease
Endothelial Dysfunction

Interventions: Biological: Peripheral Intravenous (IV) infusion of LMSCs

First Posted Date: 2015-10-27

Last Posted Date: 2023-02-16

Lead Sponsor: Longeveron Inc.

Registration Number: NCT02587572

Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome

Phase 1

Terminated

Conditions: Hypoplastic Left Heart Syndrome

Interventions: Drug: Allo-hMSCs
Drug: Placebo

First Posted Date: 2015-03-25

Last Posted Date: 2021-07-19

Lead Sponsor: Longeveron Inc.

Target Recruit Count: 5

Registration Number: NCT02398604

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery

Phase 1

Completed

Conditions: Frailty

Interventions: Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Biological: Placebo

First Posted Date: 2014-02-17

Last Posted Date: 2021-07-14

Lead Sponsor: Longeveron Inc.

Target Recruit Count: 65

Registration Number: NCT02065245

Locations: 🇺🇸
ISCI/University of Miami Miller School of Medicine, Miami, Florida, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy